A retrospective observational study assessing the incidents of acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors
Latest Information Update: 29 Aug 2022
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 01 Sep 2022 Results published in the International Immunopharmacology
- 29 Aug 2022 New trial record